866-997-4948(US-Canada Toll Free)

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 58 Pages

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017

Summary

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1). The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 4 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion, Retinopathy and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics and enlists all their major and minor projects
- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
Alteogen Inc
CSL Ltd
Eli Lilly and Company
Formycon AG
Regeneron Pharmaceuticals Inc
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
(aflibercept + nesvacumab) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones
Featured News & Press Releases
May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017
Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease
Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia
Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS
Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists guidance
May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection
Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven
Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept)
Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Sep 25, 2015: Bayers Eye Drug Recommended for EU Approval in Fifth Indication
Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema
Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition
Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan
Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance
May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Alteogen Inc, H1 2017
Pipeline by CSL Ltd, H1 2017
Pipeline by Eli Lilly and Company, H1 2017
Pipeline by Formycon AG, H1 2017
Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Dormant Projects, H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *